Das Asha 4
4 · PROGENICS PHARMACEUTICALS INC · Filed Jun 23, 2020
Insider Transaction Report
Form 4
Das Asha
Chief Medical Officer
Transactions
- Disposition to Issuer
Stock Option (Right to Buy)
2020-06-19−82,214→ 0 totalExercise: $4.77Exp: 2030-03-02→ Common Stock (82,214 underlying) - Disposition to Issuer
Stock Option (Right to Buy)
2020-06-19−125,000→ 0 totalExercise: $4.56Exp: 2029-02-01→ Common Stock (125,000 underlying)
Footnotes (3)
- [F1]This option is scheduled to vest in annual installments over the five-year period commencing February 1, 2019.
- [F2]On June 19, 2020, pursuant to the Amended and Restated Agreement and Plan of Merger, dated February 20, 2020 (the "Merger Agreement") among Lantheus Holdings, Inc. ("Lantheus"), Plato Merger Sub, Inc., a wholly-owned subsidiary of Lantheus ("Merger Sub"), and Progenics Pharmaceuticals, Inc. ("Progenics"), Merger Sub merged with and into Progenics (the "Merger"), with Progenics surviving as a wholly-owned subsidiary of Lantheus. At the effective time of the Merger, this option was assumed by Lantheus and converted into an option to purchase Lantheus common stock based on an exchange ratio of 0.31 of a share of Lantheus common stock for each share of Progenics common stock subject to the option (with a corresponding adjustment being made to the exercise price of the option). Except for these adjustments, the current vesting and other terms of the option continue in effect.
- [F3]This option is scheduled to vest in annual installments over the three-year period commencing March 2, 2020.